IN.PACT AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
Medtronic Vascular, Inc. · Decision date Feb 13, 2026
What did the FDA decide?
FDA records P190008/S046 as a supplement to PMA P190008, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 13, 2026.
FDA approval order statement
updates to the crossing profile lot release test method for the IN.PACT Admiral and AV Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 13, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P190008/S046
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular, Inc.
- Product code
- PRC
- Decision code
- OK30
- Decision date
- Feb 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-coated peripheral transluminal angioplasty catheter.
- Applicant
- Medtronic Vascular, Inc.
- Product code
- PRC
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P190008/S044 · Related supplement
IN.PACT AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter
P190008/S045 · Related supplement
IN.PACT AV Paclitaxel-coated PTA Balloon Catheter
P190008/S046 received
Application receipt date recorded by FDA.
P190008/S038 · Related supplement
IN.PACT AV Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter
P190008/S046 · FDA decision
30-Day Notice
P190008/S047 · Related supplement
IN.PACT AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter
P190008/S048 · Related supplement
IN.PACT AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
P190008/S049 · Related supplement
IN.PACT AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
Timeline entries are records held by MedtechLedger for P190008. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190008
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA supplement | Aug 12, 2025 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Sep 16, 2025 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Jan 30, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Apr 23, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | May 1, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | May 21, 2026 | FDA |
Explore the linked device profile
Other records with product code PRC
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Lutonix 018 Drug Coated Balloon PTA CatheterP170003/S029 | Lutonix | PMA supplement | Jul 9, 2026 | FDA |
Lutonix 018 (Model 9014)P170003/S028 | Lutonix | PMA supplement | Sep 4, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P190008/S046
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
